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In Niemann-Pick type C disease, the most prevalent I1061T mutation inhibits folding and trafficking of the
NPC1 protein to the endosomes/lysosomes. In this issue of Chemistry & Biology, Ohgane and colleagues
used pharmacological chaperones to repair the defect and identify a second sterol-binding site.Niemann-Pick type C (NPC) disease is a
fatal, neurodegenerative genetic disease
characterized by massive cholesterol
accumulation in late endosomes/lyso-
somes (endo-lysosomes). NPC is mainly
caused by mutations in the NPC1 gene
(95% of patients) that encodes a protein
responsible for cholesterol efflux from
the endo-lysosomes (Karten et al., 2009).
NPC1 is a polytopic membrane protein.
It consists of 1,278 amino acids (Carstea
et al., 1997) that are organized to form
a lumenal cholesterol-binding site at the
N-terminal region (head) (Kwon et al.,
2009), followed by a hydrophobic tail con-Figure 1. NPC1 and Cholesterol Transport from Endo-lysosomes
(a) Cholesterol esters in the form of LDL bind to the LDL receptor and are en-
docytosed and delivered to the lysosome/late endosomes.
(b) Cholesterol esters (red ball and stick) released from LDL interact with
a complex of NPC2 and acid lipase.
(c) Fatty acid chains are removed from the cholesterol esters by acid lipase to
yield NPC2-cholesterol complexes.
(d) Cholesterol is transferred to the N-terminal domain (NTD, ‘‘head’’) of NPC1.
(e) Cholesterol is exported from the endo-lysosomes by an unknown NPC1-
mediated mechanism.
(f) Mutations such as I1061T or DNTD-I1061T NPC1 (X) inhibit the folding and
trafficking of NPC1 from the ER to endo-lysosomes via the Golgi. Trapping of
NPC1 in the ER causes cholesterol to accumulate in the endo-lysosomes.
(g) Pharmacological chaperones (hexagon) rescue the full-length I1061T or the
DNTD-I1061T NPC1 truncation mutant.taining 13 transmembrane
(TM) segments. In the tail
region, there are two large
luminal loops connecting TM
segments 2 and 3 (loop 2)
and 8 and 9 (loop 3).
NPC1 exports cholesterol
out of the endo-lysosomes
after receptor-mediated en-
docytosis of LDL (see Fig-
ure 1). The mechanism of
cholesterol efflux is unknown.
NPC1 may function as
a cholesterol transporter or
permease. Another possibility
is that NPC1 mediates
cholesterol efflux by a vesic-
ular trafficking mechanism.
Although more than 200
disease-causing mutations
have been identified in
NPC1, the most prevalent is
the I1061T mutation (about
20% of disease alleles)
located in loop 3 (Park et al.,
2003). I1061T is a processing
mutation that inhibits the
folding, stability, and traf-
ficking of NPC1 to the endo-
lysosomes (Gelsthorpe et al.,
2008) (see Figure 1, step f).Reduced NPC1 levels leads to a massive
accumulation of cholesterol in the endo-
lysosomes and cell death.
It was shown that processing mutants
from other polytopic membrane proteins
such as the P-glycoprotein drug pump
(Loo and Clarke, 1997) could be rescued
when expressed in the presence of a
specific ligand (pharmacological chap-
erone) to yield a functional molecule at
the cell surface. Processing mutations
trap proteins such as P-glycoprotein or
the CFTR chloride channel as unstable,
partially folded, biosynthetic intermedi-
ates in the endoplasmic reticulum (ER)Chemistry & Biology 20, March 21, 2013with incomplete packing of the TM
segments (Chen et al., 2004; Loo et al.,
2002). A pharmacological chaperone
diffuses into the ER, where it binds to
the folding intermediate and induces it
to complete the folding process. The
folded protein is a compact protease-
resistant protein that can leave the
ER, undergo further processing in the
Golgi, and then be delivered to its proper
cellular destination (Loo and Clarke,
1998).
The I1061T NPC1 mutant is a good
candidate for pharmacological rescue,
because it is active if the protein canª2013 Elsebe induced to complete the
folding process (Gelsthorpe
et al., 2008). In this issue of
Chemistry & Biology, Ohgane
et al. (2013) demonstrated
that the I1061T NPC1 mutant
could indeed be rescued
by the ligand 25-hydroxycho-
lesterol (25HC). They then
synthesized a series of more
potent oxysterol derivatives.
Themost effective compound
was about 20-fold more
potent than 25HC. Studies
on bifunctional photoaffinity
probes further demonstrated
that the oxysterol derivatives
could directly bind to NPC1.
An exciting finding was that
these oxysterol derivatives
could have clinical potential,
because they reduced
cholesterol accumulation in
fibroblasts derived from
patients expressing the
I1061T NPC1 mutation. In
future studies, it would be
interesting to determine if
these compounds could yield
similar results with other
NPC1 processing mutants.vier Ltd All rights reserved 297
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be critical to understanding the mecha-
nism of NPC1-mediated cholesterol
efflux is that NPC1 contains a second
sterol-binding site. The authors predicted
that NPC1 might have more than one
sterol-binding site because of inconsis-
tencies between the structure-activity
studies of the oxysterol derivatives and
the crystal structure of the N-terminal
cholesterol-binding site (head piece)
(Kwon et al., 2009). To test their hypoth-
esis, they constructed an I1061T trunca-
tion mutant lacking the head piece (i.e.,
a ‘‘headless’’ NPC1 protein with amino
acids 25–248 deleted). The oxysterol
derivatives still rescued the ‘‘headless’’
NPC1-I1061T construct, and photo-
affinity labeling studies showed that the
‘‘headless’’ NPC1 contains an additional
sterol-binding site. This finding is signifi-
cant, because it suggests that the 13
TM segments may form a pore that
contains a sterol-binding site(s) or the
translocation pathway for sterol efflux.
The second sterol-binding site may also
be important for transferring cholesterol
molecules from NPC1 to an unknown298 Chemistry & Biology 20, March 21, 2013cytosolic cholesterol carrier (Figure 1,
step e).
The present study provides an impor-
tant starting point toward understanding
the mechanism of cholesterol efflux from
endo-lysosomes. It also provides evi-
dence that it might be worthwhile to
screen chemical libraries for small mole-
cules that might be better pharmacolog-
ical chaperones that may or may not
bind to a site that is different than the
second sterol-binding site. The oxysterol
derivates in this study or compounds
identified through future high throughput
screening of chemical libraries could
then be used to study the biochemistry
of NPC1 and, more importantly, could
be tested for toxicity and efficacy in clin-
ical trials. Future studies on NPC1 and
the rescue of NPC1 mutants will be very
exciting. Stay tuned.ACKNOWLEDGMENTS
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Because proteostasis networks manage the cellular proteome, their pharmacological manipulation might
correct pathologies associated with numerous protein misfolding diseases. In this issue of Chemistry &
Biology, Tong Ong and colleagues identify a novel biosynthetic juncture for glucocerebrosidase as a site
for therapeutic intervention in Gaucher’s disease.Pathologies associated with numerous
genetically-inherited conformational dis-
orders are directly manifested at the level
of the encoded protein (Kopito and Ron,
2000). The commonality among this
diverse set of disorders is the failure of
a mutant polypeptide to attain native
structure following biosynthesis, which is
often accompanied by selective pro-teolytic elimination. Intervention at this
posttranslational juncture, rather than
the alteration of an aberrant nucleotide
sequence, may provide therapeutic strat-
egies capable of correcting numerous
inherited loss-of-function disorders.
Pursuit of this novel therapeutic
endeavor was initially hindered by the
false assumption that an aberrant aminoacid sequence is solely responsible for
impairing protein conformational matura-
tion. In reality, protein folding is also in-
fluenced by the environment into which
the polypeptide is translated (Anfinsen,
1973). In support of this notion, living cells
are able to regulate numerous compart-
ment-specific stress response pathways
(Christianson et al., 2011) as a means
